Theaflavin (Black Tea Polyphenol · Cholesterol-lowering · Cardiovascular)

Compound	Theaflavin (TF1; Theaflavin-3-gallate precursor; Benztropolone-containing catechin dimer)
Chemical class	Polyphenol — Theaflavin (Benztropolone-type; oxidative condensation product of EGC and ECG/EGCG)
CAS	4670-05-7
Primary source	Camellia sinensis (fermented black tea leaves — formed during rolling/fermentation from catechin oxidation)
Key applications	Cholesterol-lowering; cardiovascular; antioxidant; antiviral
Claim strength	Moderate
Typical form	Theaflavin-standardised black tea extract (not available as routine Herbuno product); specialty theaflavin concentrate
Buy from Herbuno	Availability on request — request bulk pricing →

Name origin: Theaflavin (from "thea" — tea — and "flavin" — yellow flavonoid pigment) refers to the class of benztropolone-containing pigments that give black tea its characteristic orange-red colour. Theaflavin (TF1, the simplest theaflavin) is formed during black tea fermentation by polyphenol oxidase-catalysed condensation of (-)-epigallocatechin (EGC) and (+)-catechin, producing a dimeric benztropolone ring system. The full theaflavin family includes TF1, theaflavin-3-gallate (TF2A), theaflavin-3′-gallate (TF2B), and theaflavin-3,3′-digallate (TF3). Traditional use: Black tea has been consumed since the 17th century across Europe and Asia following the discovery of tea fermentation — either accidental or intentional depending on historical interpretation. Unlike green tea, which retains catechins, black tea's theaflavins and thearubigins were long considered the medicinally relevant constituents for cardiovascular and digestive support in Western herbal tradition. Research trajectory: Theaflavins have attracted research attention primarily for cholesterol-lowering activity — a 2003 Archives of Internal Medicine RCT (Maron et al. 2003, n=240) demonstrated significant LDL reduction with theaflavin-enriched green tea extract at 375 mg/day over 12 weeks. Antiviral activity against influenza and COVID-19 has been more recently characterised. Commercial source: Theaflavin-standardised black tea extract is not currently available in the Herbuno catalogue at compound-specific level; availability on request for specialty applications.

---

Evidence for Theaflavin Applications

Cholesterol-lowering: The Maron et al. 2003 Archives of Internal Medicine RCT (n=240 hyperlipidaemic adults, theaflavin-enriched green tea extract 375 mg/day providing 75 mg theaflavins for 12 weeks) demonstrated 11.3% reduction in total cholesterol and 16.4% reduction in LDL versus placebo, without affecting HDL. This is the primary human clinical evidence for theaflavin's cholesterol-lowering activity. The mechanism involves: bile acid binding (sequestration of bile acids by theaflavins' catechol/galloyl groups, increasing cholesterol conversion to bile acid replacement); HMG-CoA reductase modulation; and micellar cholesterol solubility reduction. Claim strength: Moderate.

Cardiovascular antioxidant: Theaflavins demonstrate high antioxidant capacity — higher than green tea catechins per mole in some assays, attributed to the benztropolone ring system's extended electron conjugation. LDL oxidation inhibition and endothelial protection (eNOS activation) have been documented in cell models. The 2003 Maron RCT showing LDL reduction also indirectly supports cardiovascular protection. Claim strength: Moderate.

Antiviral activity: Theaflavin-3,3′-digallate (TF3) demonstrates inhibitory activity against influenza neuraminidase, SARS-CoV-2 main protease (Mpro), and herpes simplex virus entry in cell-based assays. The galloyl groups contribute antiviral activity analogous to EGCG, with the benztropolone core adding additional protease binding capacity. Claim strength: Emerging.

Anti-inflammatory: NF-κB, COX-2, and NLRP3 inhibition are documented for theaflavin family members. Theaflavin-3,3′-digallate shows particularly strong NF-κB suppression, attributed to its dual galloyl groups. Claim strength: Moderate.

---

Dosage & Formulator Specification

The Maron 2003 RCT established 375 mg/day theaflavin-enriched extract (providing 75 mg total theaflavins) as the evidence-based supplement dose for LDL cholesterol reduction. Higher doses (150–300 mg theaflavins/day) have been used in subsequent studies. Standard black tea provides only 5–10 mg theaflavins per cup — making concentrated theaflavin extract necessary for therapeutic dosing.

Theaflavin-standardised black tea extract is available from specialty suppliers at 20–40% theaflavin content by HPLC. Formulation at 375 mg of 20% theaflavin extract per serving delivers the Maron 2003 study dose of 75 mg theaflavins. The full theaflavin complex (TF1 + TF2A + TF2B + TF3) is more bioactive than individual theaflavins in most comparative studies; standardisation to total theaflavins rather than TF1 specifically is the appropriate specification.

Theaflavin extract is water-soluble and compatible with solid dosage (capsule, tablet) and beverage applications. The characteristic orange colour may influence product appearance. Stability in aqueous solution is moderate — alkaline pH degrades the benztropolone ring; pH 4–6 is optimal. Compatible with statins in cardiovascular formulas (complementary but distinct mechanisms); no pharmacokinetic interactions with statins are documented at supplement doses.

No significant drug interactions are documented for theaflavins at supplement doses. Theaflavins may chelate iron (reducing non-haem iron absorption, same as catechins); separate from iron supplementation by 1–2 hours. No hepatotoxicity concerns equivalent to high-dose EGCG are established for theaflavin extract.

---

Frequently Asked Questions — Theaflavin

How do theaflavins form from green tea catechins during fermentation?
During black tea rolling and fermentation, the endogenous polyphenol oxidase enzyme in tea leaves catalyses oxidation of catechins. Pairs of catechins condense to form theaflavins: EGC + catechin → theaflavin (TF1); EGC + ECG → theaflavin-3′-gallate (TF2B); EGCG + catechin → theaflavin-3-gallate (TF2A); EGCG + ECG → theaflavin-3,3′-digallate (TF3). The benztropolone ring in each theaflavin forms from the oxidative cyclisation of the two catechins' A-ring and B-ring systems. This biosynthetic conversion explains why black tea has lower catechin content than green tea but distinct theaflavin bioactivity.

Is black tea as healthy as green tea for cardiovascular outcomes?
Black tea and green tea show broadly similar cardiovascular associations in epidemiological studies — both are associated with reduced cardiovascular mortality in large prospective cohorts. The mechanisms differ: green tea's catechins (EGCG, epicatechin) drive endothelial NO production and thermogenic COMT inhibition; black tea's theaflavins and thearubigins drive LDL-lowering via bile acid sequestration and antioxidant LDL protection. These mechanisms are complementary; combining green and black tea polyphenols in a supplement formula provides broader cardiovascular mechanistic coverage.

What are thearubigins and how do they relate to theaflavins?
Thearubigins are the high-molecular-weight (1,000–40,000 Da) polymeric pigments of black tea, formed when theaflavins further polymerise during extended fermentation and storage. They are responsible for black tea's dark colour and contribute ~60–70% of black tea dry weight. Unlike theaflavins, thearubigins are structurally heterogeneous and not well-characterised at the molecular level. Thearubigins have cardiovascular and gut prebiotic evidence but are much less studied than the defined theaflavin molecules. See the HerbIQ Thearubigins page for further detail.

Why is theaflavin extract not commercially widely available as a standalone supplement ingredient?
Producing standardised theaflavin extract requires controlled fermentation of green tea catechins (either via black tea processing or enzymatic oxidation in vitro) followed by extraction and fractionation. The yield from black tea is low relative to catechin content in green tea; specialty enzymatic oxidation of green tea catechins produces higher theaflavin yields with more control. Limited commercial awareness of theaflavins versus EGCG, combined with the technical extraction complexity, has kept theaflavin as a specialty ingredient versus mainstream green tea extract. The Maron 2003 LDL-lowering RCT data provide a commercial opportunity for dedicated theaflavin supplement development.

Related compounds: EGCG, Epicatechin, Procyanidins, Catechin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery